BrainsWay Ltd. (BWAY.TA)

BrainsWay Ltd. (BWAY.TA) — VMCI valuation read

BWAY.TA screens at VMCI 52/100, a 2-point gap above the Healthcare sector median (50). For a mid-cap BrainsWay Ltd. share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

BWAY.TA has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: BWAY.TA trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 1.2x leaves covenant headroom, which sets the rate-cycle exposure for BrainsWay Ltd..

BWAY.TA rose 2.2% over the trailing 7 days, with a +3.2% read on a 30-day basis.